Retatrutide

It is a triple receptor agonist at GLP-1, GIP and GCGR receptors. In se 2 trials, it has been shown to reduce average body weight by more than 24% in women who do not have diabetes but are in solution during pregnancy or pre-pregnancy.

Retatrutide (LY3437943) acetate engages GCGR in vivo and can improve glucose tolerance in an ipGTT through either the GIP or GLP-1 receptors. Retatrutide acetate causes great body weight loss and increases energy expenditure through glucagon receptor activatio. Retatrutide acetate can be used for the research of obesity.